[6-K] EUDA Health Holdings Ltd Current Report (Foreign Issuer)

Rhea-AI Filing Summary

EUDA Health Holdings Limited reports that the investor in its August 2025 convertible note has agreed to convert the remaining $162,500 balance of the note into 81,250 ordinary shares. This completes conversion of the initial $1,000,000 August Note, of which $837,500 had already been converted into 569,859 shares before September 19, 2025. In addition, the investor previously received 41,620 shares at a conversion price of $0.901 per share under related letter agreements. The company also states that it does not intend to send any further put requests for additional notes under the original up to $10,000,000 purchase agreement.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-40678

EUDA Health Holdings Limited

(Exact Name of Registrant as Specified in its Charter)

60 Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: +65 6327 1110

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

As previously disclosed, EUDA Health Holdings Limited (“EUDA” or the “Company”) entered into a convertible promissory note purchase agreement dated as of August 1, 2025 (the “Purchase Agreement”) with an institutional investor (the “Purchaser”) to purchase one or more convertible promissory notes (the “Notes”) in an aggregate amount not to exceed $10,000,000. Pursuant to the Purchase Agreement, the Company issued and sold to the Purchaser an initial Note in the aggregate principal amount of $1,000,000 on August 1, 2025 (the “August Note”) which was convertible into newly-issued ordinary shares of the Company, no par value (the “ordinary shares”) at 85% of the trading price of the Company’s ordinary shares on the date the Purchaser submits its conversion notice. Prior to September 19, 2025, the Purchaser had converted an aggregate of $837,500 of the August Note into 569,859 ordinary shares.

As previously disclosed, pursuant to a letter agreement by the parties dated September 19, 2025 which was further amended on October 2, 2025, the Company delivered to the Purchaser an additional 41,620 ordinary shares at the conversion price of $0.901 per share, and the Purchaser agreed not to convert the remaining $162,500 balance of the August Note until after October 31, 2025 on which date the Purchaser may opt to either convert the remaining $162,500 balance of the August Note into 81,250 ordinary shares at $2.00 per share, or request that the Company repay the $162,500 in cash. On November 7, 2025, the Purchaser agreed to convert the remaining $162,500 balance of the August Note into 81,250 ordinary shares (the “October Amendment to Letter Agreement”).

As previously disclosed, the Company does not intend to send Purchaser any additional put requests for the sale of additional Notes to the Purchaser under the terms of the Purchase Agreement.

The foregoing description of the October Amendment to Letter Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the October Amendment to Letter Agreement which is filed as Exhibit 1.1 to this Current Report, and incorporated by reference herein.

This Report on Form 6-K is incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-282723) and the prospectus thereof and any prospectus supplements or amendments thereto.

Exhibits
1.1		October Amendment to Letter Agreement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Dated: November 17, 2025
EUDA Health Holdings Limited
	/s/ Alfred Lim
By:	Alfred Lim
	Chief Executive Officer

FAQ

What did EUDA (EUDA) announce regarding its August 2025 convertible note?

EUDA announced that the investor agreed on November 7, 2025 to convert the remaining $162,500 balance of the August 2025 convertible note into 81,250 ordinary shares, fully converting that initial note.

How large was EUDAs initial August 2025 convertible note and how much was already converted?

The initial August 2025 note had an aggregate principal amount of $1,000,000, of which $837,500 had been converted into 569,859 ordinary shares before September 19, 2025.

What additional shares did the EUDA investor receive under the letter agreements?

Under a September 19, 2025 letter agreement, later amended on October 2, 2025, the investor received an additional 41,620 ordinary shares at a conversion price of $0.901 per share.

What choices did the EUDA investor have for the remaining $162,500 of the note?

The investor could either convert the remaining $162,500 into 81,250 ordinary shares at $2.00 per share after October 31, 2025, or request repayment of the $162,500 in cash. The investor chose conversion.

Does EUDA plan to issue additional notes under the $10,000,000 purchase agreement?

EUDA states that it does not intend to send any additional put requests for the sale of further notes to the investor under the purchase agreement, which allowed issuances up to an aggregate $10,000,000.

How is this EUDA 6-K related to its existing registration statement?

This report is incorporated by reference into EUDAs Form F-3 Registration Statement (File No. 333-282723), as well as the related prospectus and any supplements or amendments.